Table 1.

Cases of recurrent cancer in the needle track after definitive surgical treatment.

Study	Biopsy type	Primary carcinoma	ER	HER2	Surgery	XRT	Systemic treatment	Time to recurrence	Recurrent carcinoma	Location of recurrence
Thurfjell et al. [7]	FNA	Adenoid cystic	Unknown	Unknown	BCT	No	Unknown	4.1 years	Adenoid cystic	Breast
FNA	Invasive mucinous	Unknown	Unknown	BCT	No	Unknown	2.5 years	Invasive mucinous	Breast
FNA	Invasive tubuloductal	Unknown	Unknown	BCT	No	Unknown	2.1 years	Invasive tubuloductal	Breast
Chao et al. [8]	14G stereo CNB	Invasive ductal	−	Unknown	M	No	Unknown	1.4 years	Invasive ductal	Subcutaneous
14G CNB	Invasive ductal	+	Unknown	M	No	AC, tam	1 year	Invasive ductal	Unknown
Intra et al. [9]	FNA CNB	DCIS	+	+	M	No	No	2 years	Invasive ductal	Muscle
Uriburu et al. [10]	14G stereo CNB	Invasive mucinous	+	Unknown	M SS	No	CMF	1.9 years	Invasive with mucin	Dermis and subcutaneous
14G stereo CNB	Invasive ductal	+	−	M SS	No	Unknown	1.8 years	Invasive ductal	Dermis and subcutaneous
14G stereo CNB	Invasive ductal	+	+	M SS	No	Unknown	1.3 years	Invasive ductal	Subcutaneous
Kwo and Grotting [11]	CNB	Not specified	Unknown	Unknown	M SS	No	No	6 years	Not specified	Skin
Brouwer et al. [12]	14G CNB	Invasive ductal	+	+	M SS	No	No	1.1 years	Invasive ductal	Skin and dermis
	Invasive ductal/lobular	+	−	M SS	No	No	1.2 years	Invasive	Skin and dermis
Kawasaki et al. [13]	16G CNB	Well differentiated neuroendocrine tumor	+	−	BCT	No	Aromatase inhibitor	3.9 years	Well differentiated neuroendocrine tumor	Skin and subcutaneous tissue
Current study	10G stereo CNB	DCIS with microinvasion	−	+	M SS	No	No	1.5 years	Paget disease (DCIS)	Epidermis

FNA, fine needle aspiration; stereo CNB, stereotactic core needle biopsy; DCIS, ductal carcinoma in situ; ER, estrogen receptor; BCT, breast conserving therapy; M, mastectomy; SS, skin sparing; XRT, radiation therapy; CMF, cyclophosphamide, methotrexate, and 5-fluorocuracil; AC, adriamycin, cytoxan; tam, tamoxifen.